PCYN (Procyon) 12-1 Month Momentum %: 5.79% (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PCYN Procyon Corp PCYN
48 GF Score
Price $0.17
View Full Analysis

What is Procyon 12-1 Month Momentum %?

Procyon PCYN 48 12-1 Month Momentum % is 5.79% as of Jul. 17, 2026. GuruFocus rates PCYN with a GF Score™ of 48/100.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-07-17), Procyon's 12-1 Month Momentum % is 5.79%.

The industry rank for Procyon's 12-1 Month Momentum % or its related term are showing as below:

PCYN's 12-1 Month Momentum % is not ranked
in the Drug Manufacturers industry.
Industry Median: -13.22 vs PCYN: 5.79

Procyon  (OTCPK:PCYN) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Procyon 12-1 Month Momentum % Related Terms

PCYN vs KAYS, YCBD, CBDY: 12-1 Month Momentum % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Procyon's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Procyon 12-1 Month Momentum % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procyon's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Procyon's 12-1 Month Momentum % falls into.


PCYN
48GF Score
Procyon Corp PCYN
12-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Procyon  (OTCPK:PCYN) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of 5.79% mean?
Procyon (PCYN) has a 12-1 Month Momentum % of 5.79% as of Jul. 17, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Procyon and its competitors.
Is Procyon's 12-1 Month Momentum % too high?
Procyon's current 12-1 Month Momentum % is 5.79%. Overall, Procyon has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Procyon's 12-1 Month Momentum % compare to KAYS and YCBD?
Procyon's 12-1 Month Momentum % of 5.79% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Drug Manufacturers company?
A good 12-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Procyon and its competitors. Procyon's current 12-1 Month Momentum % is 5.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procyon stock overvalued right now?
Procyon (PCYN) has a current 12-1 Month Momentum % of 5.79%. The current 12-1 Month Momentum % is 5.79%. Procyon's overall GF Score™ is 48/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Procyon (PCYN), the current 12-1 Month Momentum % is 5.79% as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Procyon Business Description

Address 164 Douglas Road East, Oldsmar, FL, USA, 34677
Procyon Corp is a United-based company, through its subsidiary, it is engaged in developing and marketing proprietary medical products used to treat pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems. Its wound care products are sold through distributors to institutional customers such as hospitals, wound care clinics, skilled nursing facilities, home health agencies, and physicians and other healthcare practitioners. The firm's product lines are AMERX, AMERIGEL, and HELIX3 Bioactive Collagen. The skin and wound care products are marketed under the trademark AMERIGEL which contains the proprietary ingredient OAKIN which promotes wound healing and healthy skin. The corporation markets its products in the United States.
48GF Score

Get the complete analysis for PCYN

12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.17
Price